Perseus Proteomics (4882) · InitiativeRestated
Disease-Specific Targets Derived from Patient Tissues and Naked and Armed Antibody Programs
First written in FY2024. 1 of 2 entries say "Restated". Latest entry: FY2025.
2entries
2years
0from disclosures
How it moved
Same theme, other companies
Expansion of New Drug Discovery Programs and PipelineA theme 11 companies write about · 0 as a headwind · 15 as a tailwind
4 other companies' latest entry also says "Restated".
Ridges = years it wrote progress, valleys = years it wrote worse. Most hopeful companies at the back. Drag to turn, scroll to zoom, right-drag to pan. On a phone, two fingers turn and pinch to zoom; one finger scrolls the page.
Full recordFilings, disclosures and news, newest first
- FY2025RestatedAnnual report
「We hold numerous disease-specific target candidates obtained through the use of patient tissue. We are sequentially generating antibodies against these target groups and are advancing in-house development programs using a variety of platforms, including Naked and Armed antibodies.」
The company has reconfirmed its policy of advancing in-house development using multiple platforms, including Naked and Armed antibodies, based on disease-specific target candidates derived from patient tissue. - FY2024First statedAnnual report
「We hold numerous disease-specific target candidates obtained through the use of patient tissue. We are sequentially generating antibodies against these target groups and are advancing in-house development programs using a variety of platforms, including Naked and Armed antibodies.」
The company has disclosed a new program for in-house development using multiple platforms, including Naked and Armed antibodies, based on disease-specific target candidates obtained from patient tissue.